{
  "source": "PA-Notification-Gilotrif.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1036-14\nProgram Prior Authorization/Notification\nMedication Gilotrif® (afatinib)\nP&T Approval Date 10/2013, 2/2014, 2/2015, 2/2016, 6/2016, 6/2017, 6/2018, 6/2019,\n6/2020, 6/2021, 6/2022, 6/2023, 6/2024, 6/2025\nEffective Date 9/1/2025\n1. Background:\nGilotrif® (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with\nmetastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal\ngrowth factor receptor (EGFR) mutations as detected by an FDA-approved test. Gilotrif is also\nindicated for the treatment of patients with metastatic, squamous NSCLC progressing after\nplatinum-based chemotherapy.1 The National Cancer Comprehensive Network (NCCN) also\nrecommends the use of Gilotrif in patients with advanced non-nasopharyngeal head and neck\ncancers with progression on or after platinum-containing chemotherapy. Additionally, the NCCN\nalso recommends use of Gilotrif as a single-agent treatment for brain metastases in patients with\nEGFR sensitizing mutation positive NSCLC.2\nLimitations of Use: Safety and efficacy of Gilotrif were not established in patients whose tumors\nhave resistant EGFR mutations.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Gilotrif will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Non-Small Cell Lung Cancer (NSCLC)\n1. Initial Authorization\na. Gilot",
    "e approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Non-Small Cell Lung Cancer (NSCLC)\n1. Initial Authorization\na. Gilotrif will be approved based on both of the following criteria:\n© 2025 UnitedHealthcare Services, Inc.\n1\n(1) Diagnosis of metastatic non-small cell lung cancer (NSCLC)\n-AND-\n(2) One of the following:\n(a) Squamous disease progressing after previous platinum-based chemotherapy\n(b) Tumors are positive for non-resistant epidermal growth factor receptor\n(EGFR) mutations\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Gilotrif will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Gilotrif therapy.\nAuthorization will be issued for 12 months.\nC. Non- Nasopharyngeal Head and Neck Cancer\n1. Initial Authorization\na. Gilotrif will be approved based on both of the following criteria:\n(1) Diagnosis of advanced, non-nasopharyngeal head and neck cancer\n-AND-\n(2) Disease has progressed on or after platinum-containing chemotherapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Gilotrif will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Gilotrif therapy.\nAuthorization will be issued for 12 months.\nD. Brain Metastases\n1. Initial Authorization\na. Gilotrif will be approved based on the following criteria:\n(1) Diagnosis of brain metastasis due to EGFR-sensitizing mutation positive non-\nsmall cell lung cancer\n© 2025 UnitedHealthcare Services, Inc.\n2\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Gilotrif will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Gilotrif therapy.\nAuthorization will be issued for 12 months.\nE. NCCN Recommended Regimens\n1. The drug has been recognized for treatment of the cancer indication by The National\nComprehensive Can",
    "e on Gilotrif therapy.\nAuthorization will be issued for 12 months.\nE. NCCN Recommended Regimens\n1. The drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Gilotrif [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; April\n2022.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttps://www.nccn.org/professionals/drug_compendium/content/. Accessed April 30, 2025.\nProgram Prior Authorization/Notification - Gilotrif (afatinib)\nChange Control\n10/2013 New program for Gilotrif approved by FDA on 7/12/2013.\n2/2014 Review with no change to Coverage Criteria.\n2/2015 Annual review. Added coverage for HER2-positive NSCLC. Updated\nbackground and references.\n2/2016 Annual review. Changed initial and reauthorization period to 12\nmonths. Updated references.\n6/2016 Added additional coverage based on new FDA indication and NCCN\nguidelines. Updated background and references.\n© 2025 UnitedHealthcare Services, Inc.\n3\n6/2017 Added additional coverage for advanced non-nasopharyngeal head and\nneck cancer based on updated NCCN guidelines. Updated background\nand references.\n6/2018 Annual review. Updated background and criteria to align with updated\nlabeled indication. Updated refere",
    "head and\nneck cancer based on updated NCCN guidelines. Updated background\nand references.\n6/2018 Annual review. Updated background and criteria to align with updated\nlabeled indication. Updated references.\n6/2019 Annual review with no change to coverage criteria. Updated\nbackground and reference.\n6/2020 Annual review. Added brain metastases coverage based on NCCN\nguidelines. Updated background and references.\n6/2021 Annual review. Updated brain metastases coverage based on NCCN\nguidelines. Updated background and references.\n6/2022 Annual review with no changes to criteria. Updated background with\nlimitations of use and updated references.\n6/2023 Annual review. Updated background. Added state mandate footnote.\nUpdated references.\n6/2024 Annual review. No changes to clinical criteria.\n6/2025 Annual review. No changes to coverage criteria.\n© 2025 UnitedHealthcare Services, Inc.\n4"
  ]
}